Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Monday, October 20, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced the receipt of IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with BetaBart (RV-01). Additionally, the company has provided positive updates across four of its clinical programs. This marks a significant step forward in their clinical development efforts.
Price reaction · baseline $5.7 (2025-10-20 close) · hit after-hours · 2 other RADX headline(s) in the window, move may be shared
day 0 close
+6.3%
day 1
-5.2%
day 3 · peak
-6.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics received IND approval from the US FDA.
  • The company is initiating a Phase I therapeutic clinical study.
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Investor Presentations , Updates
• October 20, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• October 31, 2023
• Announcements
• November 29, 2022
• Announcements
• July 3, 2024
• Announcements
• August 14, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent approval did Radiopharm Theranostics receive?

Radiopharm Theranostics received IND approval from the US FDA.

What is the focus of the Phase I study?

The Phase I study targets B7H3 with BetaBart (RV-01).

How many clinical programs received positive updates?

Positive updates were provided across four clinical programs.

When was the capital raising announcement made?

The capital raising announcement was made on October 20, 2025.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm FDA approval BetaBart clinical study B7H3
Last updated: Oct 20, 2025